about
G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.Triple Negative Breast Cancer - An OverviewYiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231.Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer.Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patientsβ-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.Wnt modulates MCL1 to control cell survival in triple negative breast cancer.The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cellsEvaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer.Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinomaNodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatmentOrlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane TreatmentTheranostic barcoded nanoparticles for personalized cancer medicineHigh-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factorsBlocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancerPhase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial.A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents.Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer.MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.Targeted adjuvant therapy in breast cancer.A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer.Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer.
P2860
Q30845910-41ABF1F2-E125-4E1D-8642-F6F63CC5FE29Q34274285-8ED8E51F-23C7-4060-8996-9104A0A87295Q34441761-BAE5C233-95C2-4F3A-97D9-D27E939235FEQ34545864-48346E14-8274-41AA-AE4F-D272CE48EA66Q34969012-ED2813F1-CE52-4171-98AC-8762921E5D0BQ35020541-A720CD5E-A770-4CDA-B9A8-29FF00CF8767Q35058248-D31DBE96-217A-45FD-ABC3-1CE2E7A7AD25Q35101885-17DEE41F-4110-4018-B72B-66E53E687F17Q35176066-B6194EEC-B34E-494D-9701-06460ACB51A2Q36145737-9C1CB3EA-CC61-430E-A061-D32F5AAB2CFFQ36476168-AEFAB745-9E07-4BFF-A8A4-EB3F3F4EBE68Q36956874-100EDA27-228E-494C-ABC5-CF9DD4BF2116Q37013406-55935AF6-085C-4D2A-97CC-3FC42F6742EDQ37176391-956FEDB0-9EC0-4FE4-8073-E40D2DD1ED3AQ37414318-61D4AAA6-DDDA-4D0F-BB07-DA5FCAF89AADQ37420053-BA2B679F-831D-4666-BA1B-B421B2A2EE93Q37536680-76667159-FF1E-4F6C-AC66-601A5CA41D18Q37743160-CD66B9A5-7D1A-4012-8E02-34D631170002Q38433690-B2F1E0FB-8003-48F7-9AEE-CB71AB302972Q38617840-70CE1693-D230-4A2C-ABED-C095E252CE37Q38717473-01754B4B-5387-432C-9722-6AB8EDEBF4E6Q38758522-3C0207DD-49C2-4322-A5E6-1158DD5323F2Q38895915-4C0DDC04-A10B-4900-9194-24FFCC1E7330Q38980703-545058CA-BD3C-4A1C-8466-9D3F8E151A56Q41709095-AAAE42AE-D6A5-47D0-93B2-B4E33C60F834Q46251266-D76E7492-E3BD-4EAD-9E16-F20595F8A91FQ52318759-288ED66C-3F55-4202-9EB2-D80A7BCA3A2CQ55398926-D8C843A7-BBD3-47B0-AF40-26D9293FB654
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adjuvant treatments for triple-negative breast cancers.
@en
type
label
Adjuvant treatments for triple-negative breast cancers.
@en
prefLabel
Adjuvant treatments for triple-negative breast cancers.
@en
P2860
P356
P1433
P1476
Adjuvant treatments for triple-negative breast cancers.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS194
P478
23 Suppl 6
P577
2012-08-01T00:00:00Z